Two-drug regimens for HIV treatment
KM Gibas, SG Kelly, JR Arribas, P Cahn, C Orkin… - The Lancet …, 2022 - thelancet.com
Combination therapy with three antiretroviral agents has been integral to successful HIV-1
treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary …
treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary …
[HTML][HTML] Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES …
Objectives The aim of this study was to assess the efficacy of dolutegravir plus lamivudine
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings
Background This work aims to evaluate integrase resistance and its predictors in HIV-1
infected combined antiretroviral therapy (cART) experienced individuals failing a …
infected combined antiretroviral therapy (cART) experienced individuals failing a …
HIV-1 subtype C drug resistance mutations in heavily treated patients failing integrase strand transfer inhibitor-based regimens in Botswana
KK Seatla, D Maruapula, WT Choga, T Ntsipe… - Viruses, 2021 - mdpi.com
There are limited real-world mutational and virological outcomes data of treatment-
experienced persons diagnosed with HIV-1 subtype C (HIV-1 C) who are failing Integrase …
experienced persons diagnosed with HIV-1 subtype C (HIV-1 C) who are failing Integrase …
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV …
D Podzamczer, A Imaz, A Lopez-Lirola… - Journal of …, 2023 - academic.oup.com
Objectives To evaluate the efficacy and safety of the two-pill regimen bictegravir/
emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat as a switching …
emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat as a switching …
[PDF][PDF] 多替拉韦用于艾滋病治疗的临床应用
肖然， 付强， 杜小莉， 李太生 - 中国药学杂志, 2023 - journal11.magtechjournal.com
目的通过分析多替拉韦(DTG) 的临床试验数据, 为优化基于DTG 的抗反转录病毒疗法(ART)
提供参考. 方法检索国内外有关DTG 的文献, 对DTG 的药效学特性, 药动学特性 …
提供参考. 方法检索国内外有关DTG 的文献, 对DTG 的药效学特性, 药动学特性 …
HIV drug resistance
C Chu, L Pollock, RW Shafer - Fundamentals of HIV Medicine …, 2023 - books.google.com
Approximately 35% of persons with diagnosed HIV infection in the United States do not have
a suppressed viral load (Centers for Disease Control and Prevention, 2022), underscoring …
a suppressed viral load (Centers for Disease Control and Prevention, 2022), underscoring …
Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART
Y Zhao, J Voget, I Singini, Z Omar, V Mudaly… - … African Journal of HIV …, 2024 - journals.co.za
Background In South African antiretroviral guidelines, selected patients failing second-line
protease inhibitor (PI)-based therapy qualify for genotypic resistance testing–those with PI …
protease inhibitor (PI)-based therapy qualify for genotypic resistance testing–those with PI …
[PDF][PDF] HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana. Viruses …
KK Seatla, D Maruapula, WT Choga… - DOI: https://doi. org …, 2021 - academia.edu
There are limited real-world mutational and virological outcomes data of
treatmentexperienced persons diagnosed with HIV-1 subtype C (HIV-1 C) who are failing …
treatmentexperienced persons diagnosed with HIV-1 subtype C (HIV-1 C) who are failing …